Search results for "Replacement"

showing 10 items of 561 documents

The mechanisms of thrombotic risk induced by hormone replacement therapy.

2001

Abstract Objective : To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions : Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemosta…

Blood PlateletsMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentCoronary DiseaseDiseaseBioinformaticsFibrinogenGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundRisk FactorsInternal medicineFibrinolysismedicineHumansHormone replacement therapyEndothelial dysfunctionAgedVenous ThrombosisHemostasisFactor VIIbusiness.industryAntithrombinEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle Agedmedicine.diseasePostmenopauseEndocrinologyPhenotypechemistryHemostasisFemaleEndothelium Vascularbusinessmedicine.drugMaturitas
researchProduct

The effect of hormone replacement therapy on Ca2+ mobilization and P-selectin (CD62P) expression in platelets examined under flow cytometry.

2004

A series of events, such as increase of cytoplasmic free calcium (Ca 2+ ) and expression of P-selectin (CD62P), an adhesion molecule, on the platelet surface, are significant indicators of platelet activation. We have used flow cytometry to examine Ca 2+ mobilization and CD62P expression in platelets in whole blood obtained in women prior to, and after, different forms of hormone replacement therapy. Thirty-two women completed a protocol consisting of two consecutive 1-month periods under oestradlol (E 2 ), administered orally (2 mg/day) or transdermally (50 μg/day) in random order, followed by a 4-week transdermal sequential regime, in which, during the last 14 days, either progesterone (3…

Blood Plateletsmedicine.medical_specialtyCytoplasmP-selectinHormone Replacement Therapychemistry.chemical_compoundInternal medicinemedicineMedroxyprogesterone acetateHumansPlateletPlatelet activationWhole bloodTransdermalEstradiolHematologyGeneral MedicineMiddle AgedPlatelet ActivationAdenosine diphosphateP-SelectinEndocrinologychemistryGene Expression RegulationCalciumFemaleMenopauseHormonemedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Sustained low-efficiency dialysis (SLED) for acute lithium intoxication

2008

Acute lithium intoxication may cause serious neurologic and cardiac manifestations, up to the patient's death. Owing to its low molecular weight, relatively small volume of distribution close to that of total body water, and its negligible protein binding, lithium can be efficiently removed by any extracorporeal modality of renal replacement therapy (RRT). However, the shift from the intracellular to the extracellular compartment, with the inherent rebound phenomenon after the end of RRT, might limit the efficacy of the conventional, short-lasting haemodialysis. There have been no published studies up to now concerning the use of sustained low-efficiency dialysis (SLED) in lithium intoxicat…

Bradycardiamedicine.medical_specialtyLithium (medication)medicine.medical_treatmentCase Reportchemistry.chemical_compoundOliguriamedicineRenal replacement therapyDialysisbipolar disorderTransplantationbusiness.industryLithium carbonateGastric lavagedrug toxicitypsychotropic drugsSurgerychemistrylithiumNephrologyAnesthesiadialysisHemodialysismedicine.symptombusinessmedicine.drugClinical Kidney Journal
researchProduct

Impact of orphan drugs on Latvian budget

2016

Background Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. Methods Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total pharmaceuti…

Budgetsendocrine systemOrphan Drug ProductionCost-Benefit AnalysisPharmacology toxicologyPharmacologyOrphan drug03 medical and health sciences0302 clinical medicineOrphan Drug ProductionOrphan drugsHumansEnzyme Replacement TherapyGenetics(clinical)Pharmacology (medical)030212 general & internal medicinehealth care economics and organizationsGenetics (clinical)ReimbursementMucopolysaccharidosis IIMedicine(all)Public economicsCost–benefit analysisResearch030503 health policy & servicesExpenditureLatvianGeneral MedicineBudget impactLatviaReimbursementlanguage.human_languageBudget impactlanguageBusiness0305 other medical scienceRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 func…

2015

AbstractBreast cancer is a heterogeneous disease and approximately 70% of newly diagnosed breast cancers are estrogen receptor (ER) positive. Out of the two ER types, α and β, ERα is the only ER that is detectable by immunohistochemistry in breast cancer biopsies and is the predominant subtype expressed in breast tumor tissue. ER-positive tumors are currently treated with anti-hormone therapy to inhibit ER signaling. It is well known that breast cancer cells can develop endocrine resistance and resistance to anti-hormone therapy and this can be facilitated via the autophagy pathway, but so far the description of a detailed autophagy expression profile of ER-positive cancer cells is missing.…

Cancer ResearchProgrammed cell deathImmunologyEstrogen receptorBreast NeoplasmsBiologyBAG3Cellular and Molecular NeuroscienceNeuroblastomaBreast cancermedicineAutophagyEstrogen Receptor betaHumansPrecision MedicineEstrogen receptor betaPI3K/AKT/mTOR pathwayAdaptor Proteins Signal TransducingEstrogen Replacement TherapyEstrogen Receptor alphaCell Biologymedicine.disease3. Good healthCell biologyGene Expression Regulation NeoplasticCancer cellMCF-7 CellsOriginal ArticleFemaleApoptosis Regulatory ProteinsEstrogen receptor alphaSignal TransductionCell Death & Disease
researchProduct

DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women

2019

Aim: Use of menopausal hormone therapy (MHT) has been associated with a reduced risk for colorectal cancer, but mechanisms underlying this relationship are not well understood. In the colon, MHT appears to act through estrogen receptor β (ERβ) which may influence DNA methylation by binding to DNA. Using genome-wide methylation profiling data, we aimed to identify genes that may be differentially methylated according to MHT use. Materials & methods: DNA methylation was measured using Illumina HumanMethylation450k arrays in two independent tumor sample sets of colorectal cancer patients. Differential methylation was determined using R/limma. Results: In the discovery analysis, two CpG si…

Cancer Researchmedicine.drug_classColorectal cancermedicine.medical_treatmentEstrogen receptorBiologychemistry.chemical_compoundGeneticsmedicineEstrogen Receptor betaHumansGeneAgedAged 80 and overEstrogen Replacement TherapyHormone replacement therapy (menopause)DNA MethylationMiddle Agedmedicine.diseasechemistryCpG siteEstrogenDNA methylationCancer researchCpG IslandsFemaleMenopauseColorectal NeoplasmsDNAEpigenomics
researchProduct

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.

2006

Fabry disease is an X-linked lysosomal storage disorder characterized by multi-organ dysfunction, including hearing loss - mainly sensorineural. The recent introduction of enzyme replacement therapy (ERT) has resulted in improvements in renal and cardiac function, pain and quality of life. One study has also suggested small improvements in high-frequency hearing. In this paper, we study the effect of ERT on hearing in patients in the Europe-wide database - the Fabry Outcome Survey (FOS). Twenty-six patients in FOS had pure-tone audiometry performed up to 6 months before starting ERT with agalsidase alpha and after a median of 12 months of treatment. We assessed changes in hearing thresholds…

Cardiac function curveAdultMalemedicine.medical_specialtyHearing lossClinical BiochemistryAlpha (ethology)AudiologyBiochemistryQuality of lifeotorhinolaryngologic diseasesmedicineHumansLongitudinal Studiesmedicine.diagnostic_testbusiness.industryVascular diseaseGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryIsoenzymesTreatment OutcomeSensory Thresholdsalpha-GalactosidaseAudiometry Pure-ToneFabry DiseaseFemalemedicine.symptomAudiometrybusinessEuropean journal of clinical investigation
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

Managing service shutdowns: Cash refunds or vouchers?

2022

Service shutdowns—extended disruptions of operations—caused by exogenous events are on the rise. Such shutdowns pose major challenges for service providers, customers, and regulators. Providers prefer vouchers as a means of service recovery to limit bankruptcy risk, whereas customers demand cash refunds or vouchers that include a generous bonus. Regulators, on the other hand, insist that customers must be granted the right to be reimbursed in cash. This paper shows that a zero bonus is optimal under the voucher-only strategy, whereas the provider should always include a positive bonus with the voucher under the hybrid strategy that allows customers to choose between the cash refund and vouc…

Cash refundMarketingService failure and recoveryService shutdownVoucherService replacementInternational Journal of Research in Marketing
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct